Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds
1. AMPH's Q4 EPS of 92 cents missed estimates by 2 cents. 2. Sales rose 20% year-over-year but fell short of expectations. 3. Primatene MIST exceeded $100 million in annual sales despite competitive pressures. 4. BAQSIMI sales grew significantly, contributing $41.8 million in Q4 alone. 5. JP Morgan maintains Overweight rating with a price target of $45.